Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence

[1]  J. Cadet,et al.  Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats , 1991, Brain Research Bulletin.

[2]  R. Burke,et al.  An assessment of the validity of densitometric measures of striatal tyrosine hydroxylase-positive fibers: relationship to apomorphine-induced rotations in 6-hydroxydopamine lesioned rats , 1990, Journal of Neuroscience Methods.

[3]  M. Caron,et al.  Molecular cloning and expression of the gene for a human D1 dopamine receptor , 1990, Nature.

[4]  C. Marsden.  Parkinson's disease , 1940, The Lancet.

[5]  G. Jackson,et al.  Role of nerve growth factor in oxidant‐antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance , 1990, Journal of neuroscience research.

[6]  J. Sladek,et al.  Dopamine cell replacement: Parkinson's disease. , 1990, Annual review of neuroscience.

[7]  C. Tanner,et al.  The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.

[8]  H. Chapel,et al.  CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN , 1989, The Lancet.

[9]  S. Fahn.  The Endogenous Toxin Hypothesis of the Etiology of Parkinson's Disease and a Pilot Trial of High‐Dosage Antioxidants in an Attempt to Slow the Progression of the Illness , 1989, Annals of the New York Academy of Sciences.

[10]  M. A. Ariano,et al.  Direct visualization and cellular localization of D1 and D2 dopamine receptors in rat forebrain by use of fluorescent ligands. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Cohen,et al.  Studies on the Formation of 6‐Hydroxydopamine in Mouse Brain After Administration of 2,4,5‐Trihydroxyphenylalanine (6‐HydroxyDOPA) , 1989, Journal of neurochemistry.

[12]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence , 1989, Brain Research.

[13]  S. Fahn.  Adverse Effects of Levodopa in Parkinson’s Disease , 1989 .

[14]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[15]  G. Allen,et al.  Striatal grafts provide sustained protection from kainic and quinolinic acid-induced damage , 1988, Experimental Neurology.

[16]  S. Finklestein,et al.  Increased basic fibroblast growth factor (bFGF) immunoreactivity at the site of focal brain wounds , 1988, Brain Research.

[17]  A. Dwork,et al.  Non-chromaffin tissue plus nerve growth factor reduces experimental parkinsonism in aged rats , 1988, Brain Research.

[18]  F. Hefti,et al.  Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth, and expression of transmitter-specific enzymes , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  D. Gash,et al.  Nerve-cell grafting in Parkinson's disease. , 1988, Journal of neurosurgery.

[20]  C. Altar,et al.  Topography of substantia nigra innervation by D1 receptor-containing striatal neurons , 1987, Brain Research.

[21]  J. Rosenstein.  Neocortical transplants in the mammalian brain lack a blood-brain barrier to macromolecules. , 1987, Science.

[22]  J W Langston,et al.  MPTP: current concepts and controversies. , 1986, Clinical neuropharmacology.

[23]  M. Brightman,et al.  Alterations of the blood‐brain barrier after transplantation of autonomic ganglia into the mammalian central nervous system , 1986, The Journal of comparative neurology.

[24]  C. Cotman,et al.  Transplants of purified astrocytes promote behavioral recovery after frontal cortex ablation , 1986, Experimental Neurology.

[25]  S. Snyder,et al.  MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. , 1986, Neurology.

[26]  S. Snyder,et al.  Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  T. Dawson,et al.  D-1 dopamine receptors in the rat brain: autoradiographic localization using [3H]SCH 23390. , 1985, European journal of pharmacology.

[28]  P. Morméde,et al.  Immunoreactive fibroblast growth factor in cells of peritoneal exudate suggests its identity with macrophage-derived growth factor. , 1985, Biochemical and biophysical research communications.

[29]  R. Schwarcz,et al.  II: Excitotoxic models for neurodegenerative disorders , 1984 .

[30]  A. Björklund,et al.  Fetal mesencephalic neurons survive and extend long axons across peripheral nervous system grafts inserted into the adult rat striatum , 1984, Neuroscience Letters.

[31]  C. Sladek,et al.  Vasopressin in reaggregated cell cultures of the developing hypothalamus , 1984, Brain Research Bulletin.

[32]  J. Goldman,et al.  Growth Kinetics, Cell Shape, and the Cytoskeleton of Primary Astrocyte Cultures , 1984, Journal of neurochemistry.

[33]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[34]  F. Kauffman,et al.  Muscarinic receptor binding and oxidative enzyme activities in the adult rat superior cervical ganglion: effects of 6-hydroxydopamine and nerve growth factor , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  J. Olney.  Excitotoxins: An Overview , 1983 .

[36]  J. Langston,et al.  Aetiology of Parkinsońs disease , 1983 .

[37]  H. Thoenen,et al.  New neurotrophic factors. , 1983, Annual review of physiology.

[38]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[39]  J. Crapo,et al.  Biology of disease: free radicals and tissue injury. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[40]  C. Cotman,et al.  Brain injury causes a time-dependent increase in neuronotrophic activity at the lesion site. , 1982, Science.

[41]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[42]  C. Pycock.  Turning behaviour in animals , 1980, Neuroscience.

[43]  D. Gash,et al.  Vasopressin neurons grafted into Brattleboro rats: Viability and activity , 1980, Peptides.

[44]  G Jonsson,et al.  Chemical neurotoxins as denervation tools in neurobiology. , 1980, Annual review of neuroscience.

[45]  C. Mytilineou,et al.  Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. , 1976, The Journal of pharmacology and experimental therapeutics.

[46]  A. Herbet,et al.  Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system , 1976, Brain Research.

[47]  G. Cohen,et al.  The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.

[48]  U. Ungerstedt,et al.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.

[49]  G. Breese,et al.  Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. , 1970, The Journal of pharmacology and experimental therapeutics.

[50]  U. Ungerstedt,et al.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.